Source: Eur Respir J, 51 (3) 1701875; 10.1183/13993003.01875-2017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Aurélien Justet, Gabriel Thabut, Effrosyni Manali, Maria Molina Molina, Caroline Kannengiesser, Jacques Cadranel, Vincent Cottin, Anne Gondouin, Hilario Nunes, Eline Magois, Cécile Tromeur, Grégoire Prevot, Spyros Papiris, Sylvain Marchand-Adam, Anne Sophie Gamez, Martine Reynaud-Gaubert, Lidwine Wemeau, Bruno Crestani, Raphael Borie. Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. Eur Respir J, 51 (3) 1701875; 10.1183/13993003.01875-2017

Member's Comments

No comment yet.

Related content which might interest you: Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation Source: Eur Respir J, 57 (2) 2003198; 10.1183/13993003.03198-2020 Year: 2021 Tolerance and efficacy of antifibrotic treatments in IPF patients carriying telomere related gene mutations Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Long-term safety and efficacy of ivacaftor in subjects with CF who have the G551D-CFTR mutation Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease Year: 2012 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Clinical efficacy of 1st line EGFR-TKIs for NSCLC habouring EGFR mutation with high PD-L1 expression; A single-centered retrospective study Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Doxofylline: Efficacy and safety in complex treatment of COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy Source: Eur Respir J 2016; 47: 889-897 Year: 2016 Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Clinical outcomes after lung transplantation for fibrosis in telomerase related genes mutation carriers Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes Year: 2019 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Safety and tolerability of differing sputum induction methods in normal subjects Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002 Clinical synergism of LABA/LAMA combinations in COPD patients Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001 Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016 Efficacy and safety of nintedanib in the elderly patient with IPF Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Safety and pharmacokinetics of nintedanib plus sildenafil in the INSTAGE trial Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Outcomes of NSCLC patients with positive EGFR mutation Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Phenotype and outcome of PAH patients carrying a TBX4 mutation Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension Year: 2020